CTLA-4 correlates with immune and clinical characteristics of glioma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CTLA-4 correlates with immune and clinical characteristics of glioma
Authors
Keywords
-
Journal
Cancer Cell International
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-07
DOI
10.1186/s12935-019-1085-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors
- (2019) Ioannis Kaffes et al. OncoImmunology
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models
- (2018) Vassilis Genoud et al. OncoImmunology
- TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
- (2017) William C. Dougall et al. IMMUNOLOGICAL REVIEWS
- The immune contexture in cancer prognosis and treatment
- (2017) Wolf H. Fridman et al. Nature Reviews Clinical Oncology
- Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
- (2017) Tiffany R. Hodges et al. NEURO-ONCOLOGY
- Immune Checkpoint in Glioblastoma: Promising and Challenging
- (2017) Jing Huang et al. Frontiers in Pharmacology
- PD-1 related transcriptome profile and clinical outcome in diffuse gliomas
- (2017) Shuai Liu et al. OncoImmunology
- Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model
- (2017) Cameron S. Field et al. OncoImmunology
- Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma
- (2017) Abhishek D. Garg et al. OncoImmunology
- Tumor infiltrating immune cells in gliomas and meningiomas
- (2016) Patrícia Domingues et al. BRAIN BEHAVIOR AND IMMUNITY
- Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma
- (2016) Zheng Wang et al. OncoImmunology
- Immune infiltration, glioma stratification, and therapeutic implications
- (2016) Manny D. Bacolod et al. Translational Cancer Research
- Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model
- (2016) Mao Ouyang et al. PLoS One
- Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment
- (2015) S. Scala CLINICAL CANCER RESEARCH
- Structural and functional features of central nervous system lymphatic vessels
- (2015) Antoine Louveau et al. NATURE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- circlize implements and enhances circular visualization in R
- (2014) Zuguang Gu et al. BIOINFORMATICS
- Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
- (2014) Xiaozhou Fan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
- (2013) Zheng Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production
- (2013) Stefania Laurent et al. Journal of Translational Medicine
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas
- (2013) T. Doucette et al. Cancer Immunology Research
- Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer
- (2012) Sandra Salvi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cancer and Innate Immune System Interactions
- (2012) Yanan Liu et al. JOURNAL OF IMMUNOTHERAPY
- Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients
- (2012) Brendan Fong et al. PLoS One
- pROC: an open-source package for R and S+ to analyze and compare ROC curves
- (2011) Xavier Robin et al. BMC BIOINFORMATICS
- The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy
- (2011) T. Fu et al. CANCER RESEARCH
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model
- (2010) Maria R. Sorensen et al. VACCINE
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started